Lyell Immunopharma, Inc. (NASDAQ: LYEL) is a Healthcare company (Biotechnology) with a market capitalization of $336M. The Maz Rating grades it against the other companies in its sector.
Lyell Immunopharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $13.67, Lyell Immunopharma, Inc. trades at 22520.4x sales and 1.7x book value. Over the last twelve months it generated about $14924 of revenue and a net loss of $385M. It runs a gross margin of -15446.7%, an operating margin of -1354006.7% and a net margin of -1701066.7%. It shows return on equity of -107.6%, return on invested capital of -89.2% and a free cash flow yield of -41.6%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 4.02. Over the past 52 weeks the share price ranged from $7.20 to $45.00, with a beta of -0.07.
Lyell Immunopharma, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 3 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Lyell Immunopharma, Inc. (LYEL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 75.8% / 30% · Interest income / Revenue 63500.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 63.0% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 63500.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 63.0% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 63500.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 3.10% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 69.2% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 63500.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 64.7% / 33.33% · (Cash+Recv) / Total Assets 64.7% / 33.33% · Interest income / Revenue 63500.0% / 5% | Fail |
No. As of September 2026, Lyell Immunopharma, Inc. (LYEL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Lyell Immunopharma, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 63500.0% of each dividend: Lyell Immunopharma, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.